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ABSTRACT: In a healthy immune repertoire, there exists a fraction of polyreactive antibodies that can bind to a variety of
unrelated self- and foreign antigens. Apart from naturally polyreactive antibodies, in every healthy individual, there is a fraction
of antibody that can gain polyreactivity upon exposure to porphyrin cofactor heme. Molecular mechanisms and biological
signiﬁcance of the appearance of cryptic polyreactivity are not well understood. It is believed that heme acts as an interfacial
cofactor between the antibody and the newly recognized antigens. To further test this claim and gain insight into the types of
interactions involved in heme binding, we herein investigated the inﬂuence of a group of aromatic guanylhydrazone molecules
on the heme-induced antibody polyreactivity. From the analysis of SAR and the results of UV−vis absorbance spectroscopy, it
was concluded that the most probable mechanism by which the studied molecules inhibit heme-mediated polyreactivity of the
antibody is the direct binding to heme, thus preventing heme from binding to antibody and/or antigen. The inhibitory capacity
of the most potent compounds was substantially higher than that of chloroquine, a well-known heme binder. Some of the
guanylhydrazone molecules were able to induce polyreactivity of the studied antibody themselves, possibly by a mechanism
similar to heme. Results described here point to the conclusion that heme indeed must bind to an antibody to induce its
polyreactivity, and that both π-stacking interactions and iron coordination contribute to the binding aﬃnity, while certain
structures, such as guanylhydrazones, can interfere with these processes.
■ INTRODUCTION
Speciﬁcity and diversity of adaptive immune responses are
critical features for the proper functioning of the immune
system. These properties of the immune response originate
from antigenic receptors on T and B cells and circulating
immunoglobulins. It is estimated that the human immune
system can generate 1026 possible B-cell receptor sequences
from V, D, and J region recombination and somatic
hypermutations, providing enormous binding diversity.1,2 In
the early days of immunology research, it was believed that
each antibody is highly speciﬁc for a single antigen. It is now a
well-established fact that the signiﬁcant fraction of B-cell
receptors and antibodies in a healthy immune repertoire is
capable of binding to numerous structurally unrelated self- or
foreign antigens.3−7 This phenomenon often referred to as
antibody polyreactivity, contributes to the diversiﬁcation of
immune speciﬁcities and facilitates the recognition of
pathogens in the early stages of infection.
Apart from polyreactivity occurring naturally, there exist
cryptic polyreactivity that can be induced post-translationally.
Exposure to physiologically relevant redox-active substances,
such as iron ions, reactive oxygen species, and heme causes the
appearance of polyreactivity in a fraction of human
immunoglobulins.8−12 There is evidence suggesting that
heme (iron protoporphyrin IX) induces antibody polyreactiv-
ity by direct binding to the variable region of immunoglobulin
molecules. The binding site of heme most probably overlaps
with the antigen-binding site and heme is engaged in binding
to newly recognized antigens.13,14 Heme molecules contain
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aromatic pyrrole rings and other hydrophobic groups, as well
as polar, anionic carboxylate groups and an iron ion capable of
coordinative interactions. Such structure provides numerous
possibilities for noncovalent interactions with both immuno-
globulins and possible new antigens.15 However, the molecular
mechanism of the induced antibody polyreactivity is not well
understood. Additionally, there is no strategy so far for the
control of this phenomenon under physiopathological
conditions where the massive release of intracellular heme
occurs such as in hemolytic diseases.9 Thus, compounds that
have the capacity to inhibit the eﬀect of heme on antibodies
may demonstrate therapeutic activity for amelioration of the
negative proinﬂammatory eﬀects of extracellular heme in
disorders such as malaria, sickle cell disease, and autoimmune
hemolytic anemia.
To gain an insight into the type of interactions involved, we
examined the eﬀect of a series of heterocyclic guanylhydrazone
(iminoguanidine) molecules on the ability of heme to induce
polyreactivity of a prototypic human monoclonal IgG1. This
antibody (Ab21) was previously identiﬁed to gain the capacity
to bind with high aﬃnity to structurally diﬀerent protein
antigens upon heme exposure.14,16,17 The guanylhydrazone
series of molecules investigated here were chosen based on
their expected ability to bind heme by noncovalent
interactions. The studied molecules diﬀered in the number
of aromatic rings and positively charged guanylhydrazone
groups, thus providing diﬀerent possibilities for coordinative,
ionic and π-stacking interactions with heme and heme-binding
site on the immunoglobulin. We hypothesized that with the
gradual increase in the number of structural elements capable
of interacting with heme, the molecules will exhibit a stronger
inhibiting eﬀect on the heme-induced antibody polyreactivity.
Over the past few years, various compounds containing the
guanylhydrazone (iminoguanidine) moiety have attracted
much attention for their versatile biological activities. These
compounds were extensively studied for their antiviral,18,19
antiparasitic,20 antibacterial,21−23 and antifungal activities.24−26
The ability of the compounds to inhibit or induce antibody
polyreactivity was investigated using standard immunoassays
and their interactions with heme were followed by UV−vis
spectroscopic measurements. We compared the inﬂuence of
our compounds on the heme-induced polyreactivity with that
of the antimalarial drug chloroquine, which is known to bind to
heme and perturb its interactions. Chloroquine inhibits the
crystallization of toxic ferriprotoporphyrin IX to nontoxic
crystalline hemozoin by binding to monomeric or dimeric
forms of free heme, depending on the chemical environment.27
■ RESULTS AND DISCUSSION
To study the molecular interactions involved in antibody−
heme binding, we treated Ab21 with a series of guanylhy-
drazones prior to heme exposure and followed the changes in
the Ab binding potential to protein antigens. Aromatic
guanylhydrazones (Figure 1) were chosen based on their
structures that can provide the possibility for diﬀerent types of
interactions with heme. They possess positively charged
guanylhydrazone groups that can interact with carboxylates
and aromatic rings (benzene, thiophene, furan, or thiazole)
that can form noncovalent interactions with pyrrole rings.
Furthermore, a number of heteroatoms in their structure can
potentially coordinate with an iron ion in the center of the
protoporphyrin IX macrocyclic core. The studied molecules
diﬀered in the number and type of aromatic rings and
positively charged guanylhydrazone groups. The simplest
studied molecule is guanabenz, an approved drug that is
used as an antihypertensive agent.28 It is composed of only one
substituted benzene ring and one guanylhydrazone group
(Figure 1). Other synthetic iminoguanidines used in this study
were previously determined to exhibit signiﬁcant antifungal
activity.24−26 They were divided into three groups based on the
Figure 1. Structure of aromatic guanylhydrazones.
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structure complexity. The ﬁrst group of compounds (com-
pounds 1−8) contained one positively charged iminoguanidine
group and two hydrophobic aromatic rings. Molecules in the
second group (9−11) were composed of two positively
charged iminoguanidine groups and two hydrophobic aromatic
rings. The third group (12 and 13) had one additional benzene
ring compared to the second group.
Acquired Polyreactivity of Ab21. To conﬁrm heme-
sensitivity of Ab21, the binding potential to protein antigens of
native and heme-treated antibody was compared. The selected
antibody acquires a strong binding potential for both human
and bacterial antigens after heme treatment (Figure 2). After
exposure to two times molar excess of heme, there was
substantial binding of Ab21 to human factor VIII, human C3,
and human factor H, as seen in ELISA experiments (Figure
2A−C). Immunoblot analysis of the interaction of native and
heme-exposed Ab21 with immobilized Bacillus anthracis
proteins is in agreement with the conclusion that initially
nonreactive Ab21 acquires the ability to bind to diverse
antigens (Figure 2D).
Inhibition of Heme-Induced Antibody Polyreactivity.
We evaluated the eﬃcacy of guanylhydrazones to inhibit heme-
induced polyreactivity of Ab21. The antibody was treated with
a 30-fold molar excess of tested compounds, followed by the
addition of a 15-fold molar excess of heme. Binding of native
and heme-treated antibody to three human antigens was
examined by ELISA. We hypothesized that the increase in the
complexity will result in an increase of the inhibiting potential
of a given molecule since there is a higher possibility of it to
interact with heme and hence prevent heme from binding to
the IgG. The experiment demonstrated that all tested
guanylhydrazones, except for guanabenz, were able to reduce
heme-induced antibody polyreactivity. Most of the compounds
were considerably more eﬃcient inhibitors than the well-
known heme-binding compound, chloroquine. However,
contrary to our prediction, there is a trend of decrease of
inhibitory potential with an increase of the molecular
complexity (Figure 3). This may be explained by the lower
possibility for the molecules with higher complexity to adopt a
planar conformation that is necessary for the aromatic moieties
to be employed in interactions with the porphyrin ring. Under
experimental conditions applied here, compounds 1−5 were
able to completely inhibit acquired polyreactivity of Ab21. To
determine more precisely and compare inhibiting potentials of
the two most potent compounds 3 and 4, Ab21 was treated
with decreasing concentrations of 3 or 4 in the presence of a
constant concentration of hemin. The binding of treated and
non-treated antibody was followed by ELISA and western blot
(Figure 4A,C). In both experiments, compound 3 was revealed
to be more eﬃcient, given that a lower concentration was
required to completely neutralize the activating potential of
heme (approximately equimolar concentration to heme). The
estimated half-maximal inhibitory concentrations (IC50) of
compounds 3 and 4 were 3.0 and 5.5 μM, respectively. An
important point can be made for compound 11 that has methyl
substituents on the carbon of the iminoguanidine group,
compared to compound 10 that has hydrogen in the same
position. Steric hindrance adjacent to nitrogen atoms decreases
the inhibiting potential of the compound, indicating that these
nitrogen atoms play an important role in the mechanism of the
inhibition of the induced polyreactivity, possibly by coordinat-
ing iron ion of heme. This observation points to the conclusion
that guanylhydrazones interact directly with heme and block its
interaction with antibody and/or antigen. Our conclusion is
further supported by the fact that compounds 3 and 4 were
also able to completely inhibit heme-induced polyreactivity of
pooled immunoglobulin G, which is obtained from plasma of a
large number of healthy donors (IVIg), as can be seen from the
ELISA experiment (Figure 4B). Although we cannot
completely exclude the possibility that the compounds interact
with immunoglobulins, the fact that they inhibit heme-induced
polyreactivity of many diﬀerent immunoglobulins in the
mixture is in accordance with the conclusion that the
inhibitory eﬀect of the compounds is the consequence of
their interactions with heme, rather than with somatically
maturated Ab21.
Spectroscopic Investigation of Interactions of Heme
with Compounds 1−13. The interaction of heme with
diﬀerent molecules results in the changes in the Soret region of
the UV−vis absorbance spectrum of oxidized heme.29 We
hypothesized that guanylhydrazones prevent the binding of
heme to antibodies by direct interaction through π-stacking
interactions and coordination of the iron ion. To test this
assumption, we estimated the inﬂuence of the tested
compounds on the UV−vis absorbance spectrum of hemin.
The spectrum of 20 μM hemin in PBS displayed the
characteristic maximum in the Soret region, at 382 nm. The
addition of ﬁve times excess of guanylhydrazones resulted in a
red shift of the absorbance maximum and a decrease of the
absorbance intensity. Diﬀerential spectra were obtained by
subtraction of the individual spectra of hemin and the
compound from the spectra of their mixture (Figure 5, left).
Next, the percentage of the inhibition of heme-induced
antibody binding to factor VIII was plotted against the
absolute value of ΔA at the absorbance minimum of each
diﬀerential spectrum (Figure 5, right). A general trend can be
observed of the increase of inhibiting potential with the
increase of the absorbance intensity change (R2 = 0.43, p =
Figure 2. Heme-induced Ab21 polyreactivity by immunosorbent
assay (A−C) and immunoblot (D).
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0.016). The obtained data suggest that the direct interaction of
guanylhydrazones with heme is to a signiﬁcant extent
responsible for the diminished capacity of heme to induce
antigen-binding polyreactivity of the antibody.
Spectroscopic Investigation of the Inﬂuence of
Compound 3 on Antibody−Heme Interactions. It was
previously demonstrated that the binding of heme to Ab21 can
be followed by absorbance spectroscopy.14 Here, we conﬁrmed
that the exposure of 2 μM Ab21 to 16 μM hemin results in an
increase in the absorbance intensity of hemin and a substantial
red shift in the high energy region (black line in Figure 6, left),
which is consistent with binding of heme and coordination of
its central iron ion to the antibody molecule. To test the
inﬂuence of compound 3 on antibody−heme binding, we
followed the changes in the UV−vis absorbance spectrum of
the Ab21 and the hemin mixture in the presence of the
increasing concentration of compound 3. Diﬀerential spectra
(Figure 6, left) were obtained by subtracting the spectra of the
heme−compound mixture from the spectrum of the heme−
antibody−compound mixture at the same concentration of the
compound. It is clear that the compound has a strong eﬀect on
antibody−heme binding. However, due to the complexity of
possible interactions in the tri-component mixture, it is diﬃcult
to deduce the nature of the observed eﬀect. This is partially
because the binding of Ab21 has a stronger eﬀect on the hemin
spectrum than the binding of the compound. The value of ΔA
at the absorbance maximum of each diﬀerential spectrum was
plotted against the concentration of compound 3 (Figure 6,
right). It is possible that at the lower concentration of the
compound, the dominant inﬂuence on the hemin spectrum is
the blocking of the antibody−hemin binding (negative values
of ΔA). As the concentration of 3 approaches that of hemin,
the spectral shift becomes the consequence of compound−
hemin binding.
Induction of Ab21 Polyreactivity by Guanylhydra-
zones. Unexpectedly, two of the compounds studied for the
inhibition of heme-mediated Ab polyreactivity were able to
trigger antigen-binding polyreactivity of Ab21 themselves. The
antibody was treated with a 30-fold molar excess of tested
compounds, and the binding of the native and treated antibody
to three human antigens was evaluated by ELISA (Figure 7A−
C). Compounds 12 and 13 were inducing Ab21 binding to the
studied antigens between 25 and 35% of the binding observed
after exposure to heme. It is known that the IgG exposure to
Figure 3. Results of the study of inhibition of heme-induced Ab21 polyreactivity by immunosorbent assay. Binding to particular antigen was
expressed as a percentage of the binding of the heme-exposed Ab21. Binding of native Ab21 is represented by the blue line and binding of Ab21
exposed to chloroquine and heme is represented by the red line.
Figure 4. Inhibitory potential of compounds 3 and 4 determined by
immunosorbent assay (left) and immunoblot (right). Ab21 (A) or
IVIg (B) was treated with an excess of hemin and with increasing
concentrations of guanylhydrazones.
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reactive oxygen species can also lead to the development of
polyreactivity.10 When irradiated with visible light, proto-
porphyrin IX is known to produce these activated forms of
oxygen.30 Indeed, we demonstrated that the ability of
protoporphyrin IX to induce antibody binding to factor VIII
increases when the experiment is repeated under ambient light.
In contrast, the eﬃcacy of compound 13 to inﬂuence Ab−
protein binding did not depend on the presence of light
(Figure 7D), which excludes the formation of ROS as its
mechanism of action. Next, we wanted to investigate whether
13 gains polyreactivity-inducing ability because it forms a
coordination complex with iron ions present in traces in the
buﬀer solutions. To this end, Ab21 was exposed to increasing
equimolar concentrations of compound 13 and an iron salt
(FeSO4 or FeCl3), independently and in the mixture, and the
interaction with human factor VIII was elucidated by ELISA.
The curve representing the sum of absorbance values obtained
for compound 13 and iron alone was compared with that of
the mixture (Figure 8). The addition of Fe(II) or Fe(III) ions
did not signiﬁcantly inﬂuence the polyreactivity-inducing
potential of compound 13, indicating that the presence of
iron ions is not needed for the eﬀect. The results point to the
conclusion that the induction of polyreactivity occurs by the
direct interaction of a compound with the sensitive antibody,
possibly by the same mechanism as that of heme.
Cytotoxicity Assessment of Compounds 3 and 4.
Since these molecules are very eﬃcient in preventing heme
from binding to antibodies, they can serve as leads for the
development of the new class of therapeutics to be used in the
treatment of complications related to hemolytic diseases.
Previous studies have demonstrated that this class of
compounds is moderately toxic.25 Here, the antiproliferative
activity of two most potent inhibitors was tested on human
lung ﬁbroblasts by the MTT assay. The concentration of the
compound inhibiting cell growth by 50% (IC50) was 6.8 μM
for compound 3, and 8.4 μM for compound 4. Compared to
IC50 of the widely used drug chloroquine (58.0 μM), in the
assay used, compounds were 8.5 and 6.9 times more toxic,
suggesting that structural changes should be introduced to
reduce the toxicity while keeping heme binding capacity,
before the compounds can be considered for therapeutic use.
■ CONCLUSIONS
Previous data suggested that the necessary condition for heme-
mediated antibody polyreactivity is the direct binding of heme
to the antibody. To further test this premise, fourteen aromatic
guanylhydrazones have been investigated for their ability to
interact with heme and block the binding of the latter to the
selected antibody (Ab21). Tested guanylhydrazones diﬀer in
the number of positively charged iminoguanidine groups and
aromatic rings. Indeed, most of the studied molecules were
able to inhibit the induction of antigen-binding polyreactivity
to various extents. The inhibiting potential was shown to be
decreasing with the increasing complexity of the molecules.
Such result points to the conclusion that guanylhydrazones of
less complex structures interact with heme by establishing π-
stacking interactions; additional groups make it more diﬃcult
for the molecule to adopt planar conformation necessary for
the eﬃcient interaction. Other mechanisms for the more
complex molecules can be considered. Steric hindrance in the
proximity of iminoguanidine nitrogen atoms leads to the loss
of the large part of the inhibiting potential, suggesting that the
Figure 5. Left: the spectroscopic study of 20 μM hemin with 100 μM guanylhydrazones. Diﬀerential spectra were obtained by subtraction of the
individual spectra of hemin and the compound from the spectrum of their mixture. Right: the percentage of the inhibition of heme-induced
antibody binding to factor VIII plotted against the absolute value of ΔA at the absorbance minimum of each diﬀerential spectrum. Each dot
represents one compound.
Figure 6. Left: the spectroscopic study of 16 μM hemin and 2 μM Ab21, titrated with the increasing concentration (0, 1, 2, 4, 8, 16, and 32 μM) of
compound 3. Diﬀerential spectra were obtained by subtracting the spectra of the heme−compound mixture from the spectrum of the heme−
antibody−compound mixture at the same concentration of the compound. Right: the value of ΔA at the absorbance maximum of each diﬀerential
spectrum plotted against the concentration of compound 3.
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nitrogen atom is involved in an important interaction with
heme, possibly the coordination of the central metal ion.
Investigation of the inﬂuence of guanylhydrazones on the
absorbance spectra of heme demonstrated that there was a red
shift of the absorbance maximum in the Soret region and
signiﬁcant lowering of the absorbance intensity. The extent of
the change is in accordance with the hypothesis that strong
coordinative interactions with iron are formed. The correlation
between the spectral change and the inhibiting potential of the
compounds implies that they inhibit heme-induced Ab
polyreactivity by binding to heme, thus preventing the
interaction with antibodies. It is noteworthy that the inhibitory
capacity of most of the studied compounds was substantially
higher than that of chloroquine. The interaction of heme with
chloroquine is a well-elucidated archetypical case of molecular
recognition of heme by a low molecular weight heterocyclic
drug.
The surprising revelation was that two of the iminoguani-
dines were able to induce antibody polyreactivity without the
presence of heme. We excluded the possibility that they
generate reactive oxygen species under described experimental
conditions or that the polyreactivity induction is assisted by
iron ions present in solution. Thus, we concluded that they
bind directly to the antibody and act as interfacial cofactors
between the antibody and the antigen, similarly as heme does.
Signiﬁcantly lower inducing potential compared to heme
highlights the importance of the unique heme structure and a
possible contribution of coordination of heme’s iron to the
overall binding aﬃnity to the antibody.
Additionally, the ability of guanylhydrazones to inhibit
antibody polyreactivity induced by heme provides a possibility
to control the biological eﬀects of the release of large quantities
of heme into circulation, related to hemolytic diseases.
Previously found to be relatively nontoxic, these molecules
can serve as leads for the development of a new class of
therapeutics to be used in the treatment of hemolytic diseases
and autoimmunity. Furthermore, the fact that they are more
eﬃcient in preventing heme from binding to antibodies than
the well-known heme-inhibiting antimalarial agent chloro-
quine, suggests that their antimalarial activity should also be
investigated.
■ EXPERIMENTAL SECTION
Hemin, Fe(III)-protoporphyrin IX chloride, was obtained from
Frontier Scientiﬁc, Inc. (Logan, UT). Guanabenz, chloroquine
diphosphate, DMSO, and protoporphyrin IX were obtained
from Sigma-Aldrich (St. Louis, MO). All chemicals were with
the highest available purity. The synthesis of compounds 1−13
was previously described.24−26 In brief, twelve aromatic
aldehydes and one ketone were synthesized using the
Suzuki−Miyaura reaction of an aryl halide and an appropriate
boronic acid, and the ﬁnal products were obtained by a one-
step condensation reaction of aminoguanidine hydrochloride
and the corresponding carbonyl compound. Details about the
production of Ab21 are published elsewhere.31,32 Brieﬂy, this is
a human monoclonal IgG1 antibody whose variable genes
encoding the immunoglobulin heavy and light chains were
ampliﬁed from a B-cell by single-cell PCR from synovial tissue
Figure 7. (A−C) Results of the study of induction of Ab21 polyreactivity by the immunosorbent assay. The binding to particular antigen was
expressed as a percentage of the binding of the heme-exposed Ab21. (D) Induction of Ab21 polyreactivity by protoporphyrin IX and compound 13
with and without irradiation. Binding of native Ab21 is represented by the blue line.
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of rheumatoid arthritis patients, cloned in an expression vector
containing the genes encoding the constant Fc-γ1 or κ chain,
respectively, and expressed using HEK293. Ab21 was
thoroughly dialyzed against PBS containing 10% sucrose and
stored before use at −20 °C at a concentration of 12 mg/mL.
Human pooled immunoglobulin G (IVIg, Endobulin, Baxter)
was dialyzed against PBS and stored before use at −20 °C at a
concentration of 80 mg/mL. Hemin was dissolved in DMSO
to a ﬁnal concentration of 2 mM. Guanylhydrazones were
dissolved in DMSO to a ﬁnal concentration of 10 mM. The
treatment of Ab21 was always performed with freshly prepared
heme, at dim light conditions, unless stated otherwise.
Measurements of heme−compound interactions were per-
formed using following experimental setting: the UV−vis
absorbance spectra were recorded by a Cary-300 spectropho-
tometer (Agilent Technologies, Santa-Clara, CA) using 1 mL
quartz optical cells (Hellma, Jena, Germany) with a 1 cm
optical path. The spectra were recorded in the wavelength
range of 300−700 nm with a spectral resolution of 1 nm and a
bandwidth set at 2 nm. The absorbance background derived by
the buﬀer was only subtracted from each reading. Measure-
ments were performed at room temperature.
Immunosorbent Assay for Heme-Induced Ab21
Polyreactivity. Ninety-six-well polystyrene plates (Nunc
MaxiSorp) were coated with human factor VIII, human C3,
and human factor H and diluted to 2 μg/mL in PBS. After
incubation for 2 h at room temperature, the residual binding
sites on plates were blocked by PBS containing 0.25% Tween
20. For treatment, Ab21 was diluted to 500 μg/mL (3.33 μM)
and exposed to 6.67 μM ﬁnal concentration of hemin. After 10
min of incubation on ice, native and heme-exposed Ab21 was
ﬁrst diluted with PBS-T (0.05% Tween 20) to 100 μg/mL. It
was further serially diluted with PBS-T in the range of 0.097−
100 μg/mL (dilution factor of 2) and incubated for 1 h at
room temperature with plates coated with the studied proteins.
After incubation with antibodies, plates were washed
extensively with PBS-T and incubated with a peroxidase-
conjugated mouse anti-human IgG (clone JDC-10, Southern
Biotech, Birmingham, AL) for 1 h at room temperature.
Immunoreactivity of Ab21 was revealed by measuring the
absorbance at 492 nm after the addition of peroxidase
substrate, o-phenylenediamine dihydrochloride (Sigma-Al-
drich) and stopping the reaction by the addition of 2 M
HCl. Measurement of the absorbance was performed with a
microplate reader (Inﬁnite 200 Pro, Tecan).
Following sections describe variations of the procedure.
Initial and ﬁnal steps of the experiments are identical to those
described above.
Immunosorbent Assay for the Study of Inhibition of
Heme-Induced Ab21 Polyreactivity. Ab21 was diluted to 100
μg/mL and exposed to 20 μM ﬁnal concentration of tested
compounds. After 10 min of incubation on ice, compound-
treated Ab21 was exposed to 10 μM of hemin. As a positive
control, Ab21 at 100 μg/mL was treated only with 10 μM of
hemin. After 15 min of incubation on ice, native and
compound and/or heme-exposed Ab21 was ﬁrst diluted with
PBS-T (0.05% Tween 20) to a ﬁnal concentration of 10 μg/
mL and incubated for 1 h at room temperature with plates
coated with the studied proteins.
Comparison of Inhibitory Potential of Compounds 3 and
4 by Immunosorbent Assay. Ab21 was diluted to 100 μg/mL
(0.67 μM) and IVIg was diluted to 1 mg/mL (6.67 μM).
Antibody solutions were exposed to decreasing concentrations
(85.76, 42.88, 21.44, 10.72, 5.36, 2.68, 1.34, 0.67, 0.33, and 0
μM) of compound 3 or 4. After 10 min of incubation on ice,
compound-treated antibodies were exposed to 10 μM of
hemin. After 15 min of incubation on ice, native and
compound and/or heme-exposed antibodies were ﬁrst diluted
with PBS-T (0.05% Tween 20) to the ﬁnal concentrations of
10 μg/mL for Ab21 and 100 μg/mL for IVIg, and incubated
for 1 h at room temperature with a plate coated with the
studied proteins.
Immunosorbent Assay for the Study of Induction of Ab21
Polyreactivity. Ab21 was diluted to 100 μg/mL and exposed
to 20 μM ﬁnal concentration of tested compounds. As a
positive control, Ab21 at 100 μg/mL was treated with 10 μM
of hemin. After 10 min of incubation on ice, native and
compound exposed Ab21 was ﬁrst diluted with PBS-T (0.05%
Tween 20) to a ﬁnal concentration of 10 μg/mL and incubated
for 1 h at room temperature with plates coated with the
studied proteins.
Immunosorbent Assay for the Study of the Eﬀect of Iron
Ions on the Induction of Ab21 Polyreactivity by Compound
13. Ab21 was diluted to 100 μg/mL (0.67 μM) and exposed to
decreasing concentrations (85.76, 42.88, 21.44, 10.72, 5.36,
2.68, 1.34, 0.67, 0.33, and 0 μM) of compound 13, iron salt
(FeCl3 or FeSO4), or the mixture of compound and iron. After
15 min of incubation on ice, native and compound and/or
iron-exposed Ab21 was ﬁrst diluted with PBS-T (0.05% Tween
20) to a ﬁnal concentration of 10 μg/mL and incubated for 1 h
at room temperature with the plate coated with the studied
proteins.
Comparison of Inhibitory Potential of Compounds 3
and 4 by Western Blot. Bacterial antigens from B. anthracis
cell lysate were ﬁrst separated by SDS-PAGE (Novex NuPAGE
Figure 8. Eﬀect of iron(III) and iron(II) ions on the induction of
Ab21 polyreactivity by compound 13. The sum of absorbance values
for Ab21 treated with compound 13 and Ab21 treated with iron ions
is shown in red circles. Black triangles represent absorbance values for
Ab21 treated with increasing concentrations of an equimolar mixture
of compound 13 and iron ions.
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4−12% Bis-Tris gel, 1.0 mm, Life Technologies) and then
transferred onto nitrocellulose membranes using an iBlot dry
transfer system (Life Technologies). After incubation at 4 °C
overnight with PBS-Tween 0.1%, membranes were mounted in
the Miniblot apparatus (Immunetics, Boston, MA). Ab21 was
treated at a 100 μg/mL concentration in PBS, with hemin
solubilized in DMSO (ﬁnal heme concentration 2.5 μM) and
with decreasing concentrations of guanylhydrazones (100, 50,
25, 12.5, 6.25, 3.12, 1.56, 0.78, 0.39, and 0 μM). After 15 min
of incubation, native and treated Ab21 was diluted 10-fold in
PBS-Tween 0.1% and loaded on Miniblot channels. After 1 h
of incubation at room temperature, nitrocellulose membranes
were removed from the Miniblot apparatus, washed for 1 h
with PBS-Tween 0.1% and incubated with alkaline phospha-
tase-conjugated goat anti-human IgG antibody (Southern
Biotech). The enzymatic reaction was performed using the
BCIP/NBT substrate (Sigma-Aldrich).
Spectroscopic Analyses of Interaction of Heme with
Guanylhydrazone Compounds. Hemin was diluted to 20
μM in PBS. The UV−vis spectra in the absence and presence
of 100 μM ﬁnal concentration of compounds were recorded.
The UV−vis spectra of 100 μM ﬁnal concentration of
compounds in PBS were recorded. Diﬀerential spectra were
obtained after subtraction of spectra of heme and compound
alone from the spectrum the heme−compound mixture.
Spectroscopic Analyses of the Inﬂuence of Guanyl-
hydrazone Compound 3 on Antibody−Heme Interac-
tions. A mixture of Ab21 (2 μM) and hemin (16 μM) in PBS
was titrated with the increasing concentrations of compound 3
(0, 1, 2, 4, 8, 16, and 32 μM). Hemin alone at 16 μM in PBS
was titrated with the same concentrations of compound 3.
Diﬀerential spectra were obtained after subtraction of spectra
of heme and compound from the spectra of the heme−
antibody−compound mixture at the same concentration of the
compound.
Antiproliferative Activity of Chloroquine and Com-
pounds 3 and 4. Antiproliferative activity of the compounds
was tested on human lung ﬁbroblasts (MRC5; ATCC
collection) by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetra-
zolium bromide (MTT) assay. The cells were incubated in the
media containing test compounds at concentrations ranging
from 0.1 to 250 μg/mL and the cell viability was measured
after 48 h. The MRC5 cell line was cultured in RPMI-1640
medium supplemented with 100 μg/mL streptomycin, 100 U/
mL penicillin and 10% (v/v) fetal bovine serum (FBS) (all
from Sigma, Munich, Germany). The cells were maintained as
a monolayer (1 × 104 cells per well) in RPMI-1640 and grown
in a humidiﬁed atmosphere of 95% air and 5% CO2 at 37 °C.
The extent of MTT reduction was determined by measuring
the absorbance at 540 nm with a microplate reader (Inﬁnite
200 Pro, Tecan) and the cell survival was expressed as a
percentage of the control (untreated cells). Cytotoxicity is
expressed as the concentration of the compound inhibiting
growth by 50% (IC50).
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Nina Bozǐnovic:́ 0000-0002-6476-2202
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